Why More International Medical Device Manufacturers Are Entering The US Market
- 17 hours ago
- 5 min read
Tariffs are usually discussed in terms of trade policy, manufacturing costs, and geopolitics.
But in the global medical device industry, they may be doing something else entirely.
They are quietly creating the next wave of companies entering the U.S. healthcare market.
Across Southeast Asia and other emerging manufacturing hubs, medical device manufacturers that historically focused on contract production are beginning to ask a different question:
What if we sold directly into the United States ourselves?
For decades, the structure of the medical device industry was predictable. Devices were designed in the United States or Europe, manufactured in Asia, and sold under Western brands.
Tariffs, geopolitical tensions, and supply chain diversification are beginning to disrupt that model.
When that happens, regulatory access becomes a strategic advantage.
The U.S. Market Is Too Important to Ignore
The global medical device industry is enormous and still growing.
Estimates place the global market at roughly $572 billion in 2025, with projections approaching $886 billion by 2032 as healthcare demand continues to rise.
The United States alone accounts for roughly 40% of global medical device demand, making it the largest single market in the world.
For manufacturers outside the United States, access to that market can dramatically change the economics of a business.
Companies that only operate as contract manufacturers typically capture a small share of the final product value. Companies that control regulatory approval, branding, and distribution capture far more of the economic upside.
That difference explains why more international manufacturers are beginning to look seriously at entering the U.S. market themselves.
Supply Chains Are Already Moving
Global supply chains began shifting long before the most recent tariff discussions.
Pandemic-era shortages exposed the risks of concentrated manufacturing, and geopolitical tensions accelerated the push toward supply chain diversification.
Many healthcare buyers and manufacturers now pursue what is often called a “China+1” strategy, expanding production capacity into countries such as:
Malaysia
Vietnam
Thailand
India
These regions already host hundreds of medical device manufacturing facilities, including production operations run by major multinational companies.
In many cases, these factories already produce devices used in hospitals around the world.
But historically, those products have often reached the market under Western brands rather than directly from the manufacturer.
Tariffs and supply chain restructuring are beginning to challenge that structure.
The Shift From Supplier to Market Entrant
For many manufacturers, the opportunity created by these shifts is not simply more contract manufacturing.
It is the possibility of becoming a market entrant rather than just a supplier.
When a company owns the regulatory clearance for a device, it can bring that product to market under its own name, build relationships with distributors, and capture a much larger share of the value chain.
But entering the U.S. market requires navigating one of the most complex regulatory systems in healthcare.
FDA Clearance as a Gateway
The most common pathway for bringing medical devices to the U.S. market is the FDA 510(k) clearance process.
Each year, the FDA clears roughly 3,000 medical devices through the 510(k) pathway, allowing companies to demonstrate that their device is substantially equivalent to a legally marketed device already on the market.
In 2022 alone, the FDA granted over 3,200 510(k) clearances, illustrating how widely used this pathway is for bringing new devices to market.
For international manufacturers, this pathway often represents the most practical entry point into the U.S. healthcare system.
But regulatory readiness requires capabilities that many contract manufacturers historically did not need to develop.
It involves understanding:
international testing standards
regulatory documentation and submission structure
For companies that have focused primarily on production, this regulatory layer can feel unfamiliar.
Yet it is also where the strategic opportunity lies.
A New Phase of Global Medtech
The global medical device industry may be entering a new phase.
For decades, manufacturers in emerging markets played a critical role in production but rarely controlled regulatory approvals or market access.
Tariffs and supply chain diversification are beginning to change that dynamic.
Manufacturers that already have the technical capabilities to produce high-quality medical devices are now exploring whether they can also navigate regulatory pathways and bring those devices to market themselves.
In this environment, regulatory readiness becomes more than a compliance requirement.
It becomes a competitive advantage.
Tariffs may have triggered the shift.
But the companies that succeed will be the ones that turn regulatory access into a strategy for entering the world’s largest medical device market.
Why Southeast Asia Is Positioned to Capture This Shift
Several regions are benefiting from the global diversification of medical device supply chains, but Southeast Asia stands out for a few reasons.
First, the region already has significant manufacturing capacity. Countries such as Malaysia, Singapore, Thailand, and Vietnam host hundreds of medical device manufacturing facilities, including operations run by multinational companies like Abbott, Boston Scientific, Teleflex, and B. Braun.
Second, many manufacturers in the region already operate under international quality systems such as ISO 13485, the global standard for medical device quality management systems. This means the operational foundation for regulatory compliance is often already in place.
Third, Southeast Asia has become an increasingly important export base for medical devices. For example, Malaysia alone exported approximately RM37.4 billion (about $8 billion USD) in medical devices in 2023, with the United States representing one of the largest export destinations.
In other words, many companies in the region are already producing devices used in hospitals around the world. What they have not always done is bring those products to market under their own name.
Tariffs and supply chain diversification are beginning to change that calculus.
What International Manufacturers Should Be Thinking About Now
For manufacturers considering entry into the U.S. market, the opportunity created by shifting supply chains is real. But capturing it requires planning early.
Companies exploring this path should start thinking about several key questions.
Device classification
Understanding how a product is classified under the FDA regulatory system determines which pathway applies and what evidence is required.
Predicate device strategy
For devices pursuing the 510(k) pathway, identifying the right predicate device is one of the most important steps in the process.
Testing strategy
Many of the tests required for regulatory submissions follow global standards, including:
Designing testing programs with both global and U.S. regulatory requirements in mind can prevent duplicated work later.
Regulatory documentation
Manufacturers entering the U.S. market must prepare detailed documentation describing device design, testing results, risk management, and performance characteristics.
For companies that have historically focused on manufacturing rather than regulatory strategy, this layer of preparation can be unfamiliar.
But it is also what separates suppliers from companies that can successfully enter global markets.
The Opportunity Ahead
The structure of the medical device industry is evolving.
Tariffs, geopolitical shifts, and supply chain diversification are creating a moment where international manufacturers have new opportunities to move beyond contract manufacturing.
The companies that succeed in this environment will not just produce devices.
They will understand how to bring them to market.
And in the global medical device industry, that often begins with regulatory access.
